THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...
The FINANCIAL — Amgen on October 6 announced that Express Scripts will provide access to Repatha (evolocumab) through its national formulary. “Ensuring access to Repatha for appropriate patients is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results